Drugs / CVN766
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05105243 Comparator | Jan → Oct 2022 | — | Cerevance | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-02-15 | Cerevance Beta, Inc. | Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters cerevance.com ↗ |
| 2023-05-16 | Cerevance Beta, Inc. | Oral Presentation of Phase 1 Data on CVN766 at American Society of Clinical Psychopharmacology (ASCP) cerevance.com ↗ |
| 2023-01-09 | Cerevance Beta, Inc. | Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia cerevance.com ↗ |
| 2022-01-25 | Cerevance Beta, Inc. | Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766 cerevance.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVN766 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105243 ↗ |
| Action | Inhibit | “highly selective orexin-1 receptor (Ox1R) antagonist” NCT05105243 ↗ |
| Modality | Small molecule | — CHEMBL3958101 ↗ |
| Route | Oral | “6 participants will receive a single oral dose of CVN766 suspension” NCT05105243 ↗ |